In this study : 30 patients with metastatic prostate cancer who admitted to the
department of Oncology, Tishreen University Hospital, Lattakia, Syria between 2013
and 2014 were grouped according to gleason score , age and body mass index.
All pati
ent received treatment with LHRH agonist (goserelin 3,6 mg
subcutaneous injection monthly) combined with anti-androgen for two weeks.
PSA and testosterone were measured in all patients before treatment then after 1
and after 6 month and the side effects were documented.
Results post ADH treatment:
There is no relationship between body mass index and testosterone level.
Hormonal treatment with LHRH agonist reduced testosterone to 50 ng/dl in 09% of the
patients, whereas 76%of the cases achieved testosterone levels 20ng/dl.
The most common treatment-related adverse event was depression 72% , hot flash
%33 and headache 30%.
